Citigroup Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $76

Benzinga · 2d ago
Citigroup analyst Eric Joseph maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $75 to $76.